4/4
10:53 am
srpt
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death [Yahoo! Finance]
Low
Report
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death [Yahoo! Finance]
4/4
08:44 am
srpt
Sarepta Therapeutics Provides Update on ELEVIDYS
Medium
Report
Sarepta Therapeutics Provides Update on ELEVIDYS
4/3
03:32 pm
srpt
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death [Yahoo! Finance]
Low
Report
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death [Yahoo! Finance]
4/3
08:04 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Needham & Company LLC from $202.00 to $183.00. They now have a "buy" rating on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Needham & Company LLC from $202.00 to $183.00. They now have a "buy" rating on the stock.
4/3
08:00 am
srpt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
4/2
08:11 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at HC Wainwright from a "sell" rating to a "neutral" rating. They now have a $75.00 price target on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was upgraded by analysts at HC Wainwright from a "sell" rating to a "neutral" rating. They now have a $75.00 price target on the stock.
3/31
05:54 pm
srpt
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/31
01:45 pm
srpt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
3/31
09:02 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $87.00 price target on the stock, down previously from $161.00.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $87.00 price target on the stock, down previously from $161.00.
3/31
08:23 am
srpt
A recent gene therapy death shines a light on AAV safety [Yahoo! Finance]
Low
Report
A recent gene therapy death shines a light on AAV safety [Yahoo! Finance]
3/30
08:00 am
srpt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
High
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
3/29
04:22 pm
srpt
Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? [Yahoo! Finance]
High
Report
Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? [Yahoo! Finance]
3/26
08:00 pm
srpt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
3/25
10:00 am
srpt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
3/23
09:38 am
srpt
Is This Stock a Buy After a Massive 20% Drop in 1 Day? [Yahoo! Finance]
Medium
Report
Is This Stock a Buy After a Massive 20% Drop in 1 Day? [Yahoo! Finance]
3/21
10:53 am
srpt
Hansa Biopharma publishes 2024 Annual and Sustainability Reports [Yahoo! Finance]
Low
Report
Hansa Biopharma publishes 2024 Annual and Sustainability Reports [Yahoo! Finance]
3/20
02:57 pm
srpt
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More [Yahoo! Finance]
3/20
11:47 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Scotiabank from $105.00 to $80.00. They now have a "sector perform" rating on the stock.
Low
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Scotiabank from $105.00 to $80.00. They now have a "sector perform" rating on the stock.
3/20
10:17 am
srpt
Teen's death following Sarepta DMD gene therapy underscores a risk seen for decades [Yahoo! Finance]
Medium
Report
Teen's death following Sarepta DMD gene therapy underscores a risk seen for decades [Yahoo! Finance]
3/20
03:46 am
srpt
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength? [Yahoo! Finance]
Medium
Report
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength? [Yahoo! Finance]
3/19
08:04 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $124.00 to $99.00. They now have a "hold" rating on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $124.00 to $99.00. They now have a "hold" rating on the stock.
3/19
08:04 am
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "sell" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
3/18
08:08 pm
srpt
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today [Yahoo! Finance]
Medium
Report
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today [Yahoo! Finance]
3/18
06:16 pm
srpt
Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Medium
Report
Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
3/18
01:23 pm
srpt
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.
Medium
Report
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $202.00 price target on the stock.